In the BioHarmony Drug Report Database
Axicabtagene ciloleucel
Yescarta (axicabtagene ciloleucel) is a gene pharmaceutical. Axicabtagene ciloleucel was first approved as Yescarta on 2017-10-18. It has been approved in Europe to treat follicular lymphoma and large b-cell lymphoma diffuse.
Trade Name
|
Yescarta |
|---|---|
Common Name
|
axicabtagene ciloleucel |
ChEMBL ID
|
CHEMBL3989989 |
Indication
|
follicular lymphoma, large b-cell lymphoma diffuse |
Drug Class
|
Image (chem structure or protein)
